BPC-157 Quick FAQ
What is BPC-157?
BPC-157 is a small protein (called a peptide) that comes from human stomach juice. It has been studied for its possible healing effects on different tissues in the body, including the skin, muscles, tendons, and the digestive system.
What are the possible benefits?
– Anti-inflammatory effects: BPC 157/TB500 has been shown to have anti-inflammatory properties in animal models
– Injury Recovery: BPC 157/TB500 has shown promising results in animal studies for accelerating injury recovery, particularly in soft tissues like tendons and ligaments
– Tissue Healing: In animal studies, BPC-157 helped wounds heal faster, including skin injuries, burns, and muscle or tendon damage. It may help blood vessels repair themselves and improve blood flow to injured areas.
– Digestive Health: BPC-157 has shown promise in protecting the stomach and intestines from damage, such as ulcers or inflammation. It may help heal fistulas (abnormal connections between organs) and reduce side effects from medications like NSAIDs (pain relievers).
– Nervous System Support: Some research in animals suggests BPC-157 could help protect nerves and may have benefits for brain health, but this is still being studied.
What are the safety studies: So far, studies have found BPC-157 to be safe in animals and very early human trials, with very few side effects reported.
Is BPC-157 approved for medical use?
BPC 157/TB500 is not currently approved by the FDA or other regulatory agencies for medical use. It is considered an experimental compound and therefore the decision is made between you and your doctor whether this is the right treatment for you. A full discussion of risks and benefits is appropriate. There is no one size fits all approach when it comes to peptides.
How Is It Administered?
Many people who use BPC 157 use it orally or as an intramuscular injection. Both forms are effective and available at LA Ortho and Wellness. However, a skilled orthopedic surgeon or other sports medicine specialist such as Dr. Gelber can also place it near a tendon or in the joint under ultrasound guidance.
TB500 is only available as a injection. It can be combined with BPC 157 for daily intramuscular injection (with tiny insulin needles) or combined with BPC 157 in a tendon or joint injection with Dr. Gelber.
Summary
BPC-157 shows promise for helping wounds and tissues heal, protecting the digestive system, and possibly supporting nerve health. However, most of the evidence comes from animal studies, and more research will certainly help. For more information about BPC-157 in Los Angeles contact us today!
References
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Pharmaceuticals (Basel, Switzerland). 2025;18(2):185. doi:10.3390/ph18020185.
- Revised Robert’s Cytoprotection and Adaptive Cytoprotection and Stable Gastric Pentadecapeptide BPC 157. Possible Significance and Implications for Novel Mediator. Sikiric P, Seiwerth S, Brcic L, et al. Current Pharmaceutical Design. 2010;16(10):1224-34. doi:10.2174/138161210790945977.
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Seiwerth S, Milavic M, Vukojevic J, et al. Frontiers in Pharmacology. 2021;12:627533. doi:10.3389/fphar.2021.627533.
- Gastric Pentadecapeptide Body Protection Compound BPC 157 and Its Role in Accelerating Musculoskeletal Soft Tissue Healing. Gwyer D, Wragg NM, Wilson SL. Cell and Tissue Research. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8.
- Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157. Sikiric P, Seiwerth S, Rucman R, et al. Current Medicinal Chemistry. 2012;19(1):126-32. doi:10.2174/092986712803414015.
- Cytoprotective Gastric Pentadecapeptide BPC 157 Resolves Major Vessel Occlusion Disturbances, Ischemia-Reperfusion Injury Following Pringle Maneuver, and Budd-Chiari Syndrome. Sikiric P, Skrtic A, Gojkovic S, et al. World Journal of Gastroenterology. 2022;28(1):23-46. doi:10.3748/wjg.v28.i1.23.
- Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Sikiric P, Drmic D, Sever M, et al. Current Pharmaceutical Design. 2020;26(25):2991-3000. doi:10.2174/1381612826666200424180139.
- Toxicity by NSAIDs. Counteraction by Stable Gastric Pentadecapeptide BPC 157. Sikiric P, Seiwerth S, Rucman R, et al. Current Pharmaceutical Design. 2013;19(1):76-83. doi:10.2174/13816128130111.
- BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak Et Al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Sikiric P, Seiwerth S, Skrtic A, et al. Pharmaceuticals (Basel, Switzerland). 2025;18(10):1450. doi:10.3390/ph18101450.
- Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, Do We Have a Solution?. Sikiric P, Seiwerth S, Rucman R, et al. Current Pharmaceutical Design. 2017;23(27):4012-4028. doi:10.2174/1381612823666170220163219.
- Brain-Gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Sikiric P, Seiwerth S, Rucman R, et al. Current Neuropharmacology. 2016;14(8):857-865. doi:10.2174/1570159×13666160502153022.
- Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Sikiric P, Seiwerth S, Skrtic A, et al. Pharmaceuticals (Basel, Switzerland). 2025;18(6):928. doi:10.3390/ph18060928.
